nach oben

Tumor Biology

Erschienen in:

01.08.2012 | Review

Ubiquitination and the Ubiquitin–Proteasome System as regulators of transcription and transcription factorsin epithelial mesenchymal transition of cancer

verfasst von: Ioannis A. Voutsadakis

Erschienen in: Tumor Biology | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Epithelial to Mesenchymal Transition (EMT) in cancer is a process that allows cancer cells to detach from neighboring cells, become mobile and metastasize and shares many signaling pathways with development. Several molecular mechanisms which regulate oncogenic properties in neoplastic cells such as proliferation, resistance to apoptosis and angiogenesis through transcription factors or other mediators are also regulators of EMT. These pathways and downstream transcription factors are, in their turn, regulated by ubiquitination and the Ubiquitin–Proteasome System (UPS). Ubiquitination, the covalent link of the small 76-amino acid protein ubiquitin to target proteins, serves as a signal for protein degradation by the proteasome or for other outcomes such as endocytosis, degradation by the lysosome or directing these proteins to specific cellular compartments. This review discusses aspects of the regulation of EMT by ubiquitination and the UPS and underlines its complexity focusing on transcription and transcription factors regulating EMT and are being regulated by ubiquitination.

Thiery JP, Sleeman JP. Complex networks orchestrate epithelial–mesenchymal transitions. Nature Rev Mol Cell Biol. 2006;7:131–42.

Acloque H, Adams MS, Fishwick K, et al. Epithelial–mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest. 2009;119:1438–49.PubMedCentralPubMed

Strieter ER, Korasick DA. Unraveling the complexity of ubiquitin signaling. ACS Chem Biol. 2012;7:52–63.PubMedCentralPubMed

Behrends C, Harper JW. Constructing and decoding unconventional ubiquitin chains. Nat Struct Mol Biol. 2011;18:520–8.PubMed

Shukla A, Chaurasia P, Bhaumik SR. Histone methylation and ubiquitination with their cross-talk and roles in gene expression and stability. Cell Mol Life Sci. 2009;66:1419–33.PubMed

Kalluri R, Weinberg RA. The basics of epithelial–mesenchymal transition. J Clin Invest. 2009;119:1420–8.PubMedCentralPubMed

Zeisberg M, Neilson EG. Biomarkers for epithelial–mesenchymal transitions. J Clin Invest. 2009;119:1429–37.PubMedCentralPubMed

Mani SA, Guo W, Liao MJ, et al. The epithelial–mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704–15.PubMedCentralPubMed

Tarin D. The fallacy of epithelial–mesenchymal transition in neoplasia. Cancer Res. 2005;65:5996–6001.PubMed

10.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.PubMed

11.

Micalizzi DS, Farabaugh SM, Ford HL. Epithelial–mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia. 2010;15:117–34.PubMedCentralPubMed

12.

Harris TJC, Tepass U. Adherens junctions: from molecules to morphogenesis. Nat Rev Mol Cell Biol. 2010;11:502–14.PubMed

13.

Meng W, Takeichi M. Adherens junction: molecular architecture and regulation. Cold Spring Harb Perspect Biol. 2009;1:a002899.PubMedCentralPubMed

14.

Baum B, Georgiou M. Dynamics of adherens junctions in epithelial establishment, maintenance, and remodeling. J Cell Biol. 2011;192:907–17.PubMedCentralPubMed

15.

Fujita Y, Krause G, Scheffner M, et al. Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat Cell Biol. 2002;4:222–31.PubMed

16.

Palacios F, Tushir JS, Fujita Y, D’Souza-Schorey C (2005) Lysosomal targeting of E-cadherin: a unique mechanism for the down-regulation of cell–cell adhesion during Epithelia to Mesenchymal Transitions. 25: 389–402

17.

Janda E, Nevolo M, Lehmann K, et al. Raf plus TGFβ-dependent EMT is initiated by endocytosis and lysosomal degradation of E-cadherin. Oncogene. 2006;25:7117–30.PubMed

18.

Ozdamar B, Bose R, Barrios-Rodiles M, et al. Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science. 2005;307:1603–9.PubMed

19.

Viloria-Petit AM, Wrana JL. The TGFβ–Par6 polarity pathway. Linking the Par complex to EMT and breast cancer progression. Cell Cycle. 2010;9:623–4.PubMed

20.

Voutsadakis IA (2010) Ubiquitin, ubiquitination and the ubiquitin–proteasome system in cancer. Atlas Genet Cytogen Oncol Haematol. URL:// Atlas GeneticsOncology.org/Deep/UbiquitinCancerID20083.httml

21.

Schulman BA, Harper JW. Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signaling pathways. Nature Rev Mol Cell Biol. 2009;10:319–31.

22.

van Wijk SJL, Timmers HTM. The family of ubiquitin-conjugating enzymes (E2s): deciding between life and death of proteins. FASEB J. 2010;24:981–93.PubMed

23.

Deshaies RJ, Joazeiro CA. RING domain E3 ubiquitin ligases. Annu Rev Biochem. 2009;78:399–434.PubMed

24.

Li W, Ye Y. Polyubiquitin chains: functions, structures, and mechanisms. Cell Mol Life Sci. 2008;65:2397–406.PubMedCentralPubMed

25.

Amerik AY, Hochstrasser M. Mechanism and function of deubiquitinating enzymes. Biochim Biophys Acta. 2004;1695:189–207.PubMed

26.

Voutsadakis IA. Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin–proteasome system and Cox-2. J Cell Mol Med. 2007;11:252–85.PubMedCentralPubMed

27.

Wolf DH, Hilt W. The proteasome: a proteolytic nanomachine of cell regulation and waste disposal. Biochim Biophys Acta. 2004;1695:19–31.PubMed

28.

Wertz IE, Dixit VM. Signaling to NF-κB: regulation by ubiquitination. Cold Spring Harb Perspect Biol. 2010;2:a003350.PubMedCentralPubMed

29.

Wu Y, Zhou BP. TNF-α/NF-κB/Snail pathway in cancer cell migration and invasion. Br J Cancer. 2010;102:639–44.PubMedCentralPubMed

30.

Min C, Eddy SF, Sherr DH, Sonenshein GE. NF-κB and epithelial to mesenchymal transition of cancer. J Cell Biochem. 2008;104:733–44.PubMed

31.

Pham CG, Bubici C, Zazzeroni F, et al. Upregulation of Twist-1 by NF-κB blocks cytotoxicity induced by chemotherapeutic drugs. Mol Cell Biol. 2007;27:3920–35.PubMedCentralPubMed

32.

Chua HL, Bhat-Nakshatri P, Clare SE, et al. NF-κB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene. 2007;26:711–24.PubMed

33.

Vonach C, Viola K, Giessrigl B, et al. NF-κB mediates the 12(S)-HETE-induced endothelial to mesenchymal transition of lymphendothelial cells during the intravasation of breast carcinoma cells. Br J Cancer. 2011;105:263–71.PubMedCentralPubMed

34.

Bachelder RE, Yoon S-O, Franci C, et al. Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: implications for the epithelial–mesenchymal transition. J Cell Biol. 2005;168:29–33.PubMedCentralPubMed

35.

Cheng GZ, Chan J, Wang Q, et al. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res. 2007;67:1979–87.PubMed

36.

Li J, Zhou BP. Activation of β-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer. 2011;11:49.PubMedCentralPubMed

37.

Vereecke L, Beyaert R, van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol. 2009;30:383–91.PubMed

38.

Landström M. The TAK1-TRAF6 signalling pathway. Int J Biochem Cell Biol. 2010;42:585–9.PubMed

39.

Espinosa L, Bigas A, Mulero MC. Alternative nuclear functions for NF-κB family members. Am J Cancer Res. 2011;1:446–59.PubMedCentralPubMed

40.

Dechend R, Hirano F, Lehmann K, et al. The Bcl-3 oncoprotein acts as a bridging factor between NF-κB/Rel and nuclear co-regulators. Oncogene. 1999;18:3316–23.PubMed

41.

Keutgens A, Shostak K, Close P, et al. The repressing function of the oncoprotein BCL-3 requires CtBP, while its polyubiquitination and degradation involve the E3 ligase TBLR1. Mol Cell Biol. 2010;30:4006–21.PubMedCentralPubMed

42.

Viatour P, Dejardin E, Warnier M, et al. GSK3-mediated BCL-3 phosphorylation modulates its degradation and its oncogenicity. Mol Cell. 2004;16:35–45.PubMed

43.

Keutgens A, Zhou X, Shostak K, et al. BCL-3 degradation involves its polyubiquitination through a FBW7-independent pathway and its binding to the proteasome subunit PSMB1. J Biol Chem. 2010;285:25831–40.PubMedCentralPubMed

44.

Perissi V, Scafoglio C, Zhang J, et al. TBL1 and TBLR1 phosphorylation on regulated gene promoters overcomes dual CtBP and NCoR/SMRT transcriptional repression checkpoints. Mol Cell. 2008;29:755–66.PubMedCentralPubMed

45.

Haase VH. Oxygen regulates epithelial-to-mesenchymal transition: insights into molecular mechanisms and relevance to disease. Kidney Int. 2009;76:492–9.PubMedCentralPubMed

46.

Kim WY, Perera S, Zhou B, et al. HIF2α cooperates with RAS to promote lung tumorigenesis in mice. J Clin Invest. 2009;119:2160–70.PubMedCentralPubMed

47.

Chen J, Imanaka N, Chen J, Griffin JD. Hypoxia potentiates Notch signalling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. Br J Cancer. 2010;102:351–60.PubMed

48.

Xing F, Okuda H, Watabe M, et al. Hypoxia-induced Jagged2 promotes breast cancer metastasis and self-renewal of cancer stem-like cells. Oncogene. 2011;30:4075–86.PubMedCentralPubMed

49.

Scortegagna M, Martin RJ, Kladney RD, et al. Hypoxia-inducible factor-1α suppresses squamous carcinogenic progression and epithelial–mesenchymal transition. Cancer Res. 2009;69:2638–46.PubMedCentralPubMed

50.

Pantuck AJ, An J, Liu H, Rettig MB. NF-κB-dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel–Lindau inactivation in renal cell carcinomas. Cancer Res. 2010;70:752–61.PubMed

51.

Cowling VH, Cole MD. Mechanism of transcriptional activation by the Myc oncoproteins. Semin Cancer Biol. 2006;16:242–52.PubMed

52.

Yada M, Hatakeyama S, Kamura T, et al. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J. 2004;23:2116–25.PubMedCentralPubMed

53.

Yeh P-Y, Lu Y-S, Ou D-L, Cheng A-L. IκB kinases increase Myc protein stability and enhance progression of breast cancer cells. Mol Cancer. 2011;10:53.PubMedCentralPubMed

54.

Trimboli AJ, Fukino K, de Bruin A, et al. Direct evidence for epithelial–mesenchymal transitions in breast cancer. Cancer Res. 2008;68:937–45.PubMed

55.

Cho KB, Cho MK, Lee WY, Kang KW. Overexpression of c-myc induces epithelial mesenchymal transition in mammary epithelial cells. Cancer Lett. 2010;293:230–9.PubMed

56.

Smith AP, Verrecchia A, Fagà G, et al. A positive role for Myc in TGFβ-induced Snail transcription and epithelial-to-mesenchymal transition. Oncogene. 2009;28:422–30.PubMed

57.

Ma L, Young J, Prabhala H, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nature Cell Biol. 2010;12:247–56.PubMed

58.

Khew-Goodall Y, Goodall GJ. Myc-modulated miR-9 makes more metastases. Nature Cell Biol. 2010;12:209–11.PubMed

59.

Turner DP, Watson DK. ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer. Expert Rev Anticancer Ther. 2008;8:33–42.PubMed

60.

Kovar H. Context matters: the hen or egg problem in Ewing’s sarcoma. Semin Cancer Biol. 2005;15:189–96.PubMed

61.

Gupta S, Iljin K, Sara H, et al. FZD4 as a mediator of ERG oncogene-induced WNT signalling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res. 2010;70:6735–45.PubMed

62.

Sun C, Dobi A, Mohamed A, et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene. 2008;27:5348–53.PubMedCentralPubMed

63.

Cowden Dahl KD, Dahl R, Kruichak JN, Hudson LG. The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells. Neoplasia. 2009;11:1208–15.PubMedCentralPubMed

64.

Takebe A, Era T, Okada M, et al. Microarray analysis of PDGFRα⁺ populations in ES cell differentiation culture identifies genes involved in differentiation of mesoderm and mesenchyme including ARID3b that is essential for development of embryonic mesenchymal cells. Dev Biol. 2006;293:25–37.PubMed

65.

Cowden Dahl KD, Zeineldin R, Hudson LG. PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells. Mol Cancer Res. 2007;5:413–21.PubMedCentralPubMed

66.

Yuen H-F, Chan Y-K, Grills C, et al. Polyomavirus enhancer activator 3 protein promotes breast cancer metastatic progression through Snail-induced epithelial–mesenchymal transition. J Pathol. 2011;224:78–89.PubMed

67.

Vitari AC, Leong KG, Newton K, et al. COP1 is a tumour suppressor that causes degradation of ETS transcription factors. Nature. 2011;474:403–6.PubMed

68.

Vousden KH, Prives C. Blinded by the SteLight: the growing complexity of p53. Cell. 2009;137:413–31.PubMed

69.

Kashatus D, Cogwell P, Baldwin AS. Expression of the Bcl-3 proto-oncogene suppresses p53 activation. Genes Dev. 2006;20:225–35.PubMedCentralPubMed

70.

Laine A, Ronai Z. Regulation of p53 localization and transcription by the HECT domain E3 ligase WWP1. Oncogene. 2007;26:1477–83.PubMed

71.

Miyazaki K, Ozaki T, Kato C, et al. A novel HECT-type E3 ubiquitin ligase, NEDL2, stabilizes p73 and enhances its transcriptional activity. Biochem Biophys Res Commun. 2003;308:106–13.PubMed

72.

Melino G, Knight RA, Cesareni G. Degradation of p63 by Itch. Cell Cycle. 2006;5:1735–9.PubMed

73.

Dai C, Gu W. p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med. 2010;16:528–36.PubMedCentralPubMed

74.

Masuya D, Huang C, Liu D, et al. The HAUSP gene plays an important role in non-small cell lung carcinogenesis through p53-dependent pathways. J Pathol. 2006;208:724–32.PubMed

75.

Chang C-J, Chao C-H, Xia W, et al. p53 regulates epithelial–mesenchymal transition and stem cell properties through modulating miRNAs. Nature Cell Biol. 2011;13:317.PubMed

76.

Kim T, Veronese A, Pichiorri F, et al. p53 regulates epithelial–mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med. 2011;208:875–83.PubMedCentralPubMed

77.

Pinho AV, Rooman I, Real FX. p53-dependent regulation of growth, epithelial–mesenchymal transition and stemness in normal pancreatic epithelial cells. Cell Cycle. 2011;10:1312–21.PubMed

78.

Wang S-P, Wang W-L, Chang Y-L, et al. p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nature Cell Biol. 2009;11:694–704.PubMed

79.

Liu M, Casimiro MC, Wang C, et al. p21^CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc Natl Acad Sci USA. 2009;106:19035–9.PubMedCentralPubMed

80.

Zhang Y, Yan W, Chen X. Mutant p53 disrupts MCF-10A cell polarity in three-dimensional culture via epithelial-to-mesenchymal transitions. J Biol Chem. 2011;286:16218–28.PubMedCentralPubMed

81.

Kogan-Sakin I, Tabach Y, Buganim Y, et al. Mutant p53^R175H upregulates Twist1 expression and promotes epithelial–mesenchymal transition in immortalized prostate cells. Cell Death Diff. 2011;18:271–81.

82.

Ohashi S, Natsuizaka M, Wong GS, et al. Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors. Cancer Res. 2010;70:4174–84.PubMedCentralPubMed

83.

Girardini JE, Napoli M, Piazza S, et al. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell. 2011;20:79–91.PubMed

84.

Melino G. p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Diff. 2011;18:1487–99.

85.

Weisz L, Damalas A, Liontos M, et al. Mutant p53 enhances nuclear factor κB activation by tumor necrosis factor α in cancer cells. Cancer Res. 2007;67:2396–401.PubMed

86.

Jiang Z, Jones R, Liu JC, et al. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle. 2011;10:1563–70.PubMed

87.

Godar S, Ince TA, Bell GW, et al. Growth-inhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression. Cell. 2008;134:62–73.PubMedCentralPubMed

88.

Gemmill RM, Roche J, Potiron VA, et al. ZEB1-responsive genes in non-small cell lung cancer. Cancer Lett. 2011;300:66–78.PubMed

89.

De Craene B, van Roy F, Berx G. Unraveling signalling cascades for the Snail family of transcription factors. Cell Signalling. 2005;17:535–47.PubMed

90.

Wang Z, Li Y, Kong D, et al. Acquisition of epithelial–mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the Notch signaling pathway. Cancer Res. 2009;69:2400–7.PubMedCentralPubMed

91.

Bagnato A, Rosanò L. Epithelial–mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis. Cells Tissues Organs. 2007;185:85–94.PubMed

92.

Yadav A, Kumar B, Datta J, et al. IL-6 promotes head and neck tumor metastasis by inducing epithelial–mesenchymal transition via the JAK–STAT3–SNAIL signaling pathway. Mol Cancer Res. 2011;9:1658–67.PubMedCentralPubMed

93.

Stemmer V, de Craene B, Berx G, Behrens J. Snail promotes Wnt target gene expression and interacts with β-catenin. Oncogene. 2008;27:5075–80.PubMed

94.

Vincent T, Neve EPA, Johnson JR, et al. A SNAIL1–SMAD3/4 transcriptional repressor complex promotes TGF-β mediated epithelial–mesenchymal transition. Nature Cell Biol. 2009;11:943–50.PubMed

95.

Zhang L, Lei W, Wang X, et al. Glucocorticoid induces mesenchymal-to-epithelial transition and inhibits TGF-β1-induced epithelial-to-mesenchymal transition and cell migration. FEBS Lett. 2010;584:4646–54.PubMed

96.

Yook JI, Li X-Y, Ota I, et al. A Wnt-Axin2-GSK3β cascade regulates Snail1 activity in breast cancer cells. Nature Cell Biol. 2006;8:1398–14.PubMed

97.

Katoh M, Katoh M. Integrative genomic analyses of ZEB2: transcriptional regulation of ZEB2 based on SMADs, ETS1, HIF1α, POU/OCT, and NF-κB. Int J Oncol. 2009;34:1737–42.PubMed

98.

Brabletz S, Brabletz T. The ZEB/miR-200 feedback loop-a motor of cellular plasticity in development and cancer? EMBO Rep. 2010;11:670–7.PubMedCentralPubMed

99.

Xia H, Ng SS, Jiang S, et al. miR-200a-mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion. Biochem Biophys Res Commun. 2010;391:535–41.PubMed

100.

Wellner U, Schubert J, Burk UC, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nature Cell Biol. 2009;11:1487–95.PubMed

101.

Voutsadakis IA. Molecular predictors of gemcitabine response in pancreatic cancer. World J Gastrointest Oncol. 2011;3:153–64.PubMedCentralPubMed

102.

Fu J, Lv X, Lin H, et al. Ubiquitin ligase Cullin 7 induces epithelial–mesenchymal transition in human choriocarcinoma cells. J Biol Chem. 2010;285:10870–9.PubMedCentralPubMed

103.

Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449:682–8.PubMed

104.

Burguignon LYW, Wong G, Earle C, et al. Hyaluronan–CD44 interaction promotes c-Src-mediated Twist signaling, microRNA-10b expression, and RhoA/RhoC up-regulation, leading to Rho-kinase-associated cytoskeleton activation and breast tumor cell invasion. J Biol Chem. 2010;285:36721–35.

105.

Karlsson R, Pedersen ED, Wang Z, Brakebusch C. Rho GTPase function in tumorigenesis. Biochim Biophys Acta. 2009;1796:91–8.PubMed

106.

Sullivan NJ, Sasser AK, Axel AE, et al. Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells. Oncogene. 2009;28:2940–7.PubMedCentralPubMed

107.

Demontis S, Rigo C, Piccinin S, et al. Twist is substrate for caspase cleavage and proteasome-mediated degradation. Cell Death Diff. 2006;13:335–45.

108.

Hwang-Verslues WW, Chang P-H, Wei P-C, et al. miR-495 is upregulated by E12/E47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of E-cadherin and REDD1. Oncogene. 2011;30:2463–74.PubMed

109.

Sun L, Trausch-Azar JS, Ciechanover A, Schwartz AL. E2A protein degradation by the ubiquitin–proteasome system is stage-dependent during muscle differentiation. Oncogene. 2007;26:441–8.PubMed

110.

Sun L, Trausch-Azar JS, Ciechanover A, Schwartz AL. Ubiquitin–proteasome-mediated degradation, intracellular localization, and protein synthesis of MyoD and Id1 during muscle differentiation. J Biol Chem. 2005;280:26448–56.PubMed

111.

Bhat KP, Greer SF. Proteolytic and non-proteolytic roles of ubiquitin and the ubiquitin proteasome system in transcriptional regulation. Biochim Biophys Acta. 2011;1809:150–5.PubMed

112.

Jenster G, Spencer TE, Burcin MM, et al. Steroid receptor induction of gene transcription: a two-step model. Proc Natl Acad Sci USA. 1997;94:7879–84.PubMedCentralPubMed

113.

Zhang Y. Transcriptional regulation by histone ubiquitination and deubiquitination. Genes Dev. 2003;17:2733–40.PubMed

114.

Dover J, Schneider J, Tawiah-Boateng MA, et al. Methylation of histone H3 by COMPASS requires ubiquitination of histone H2B by Rad6. J Biol Chem. 2002;277:28368–71.PubMed

115.

Sun ZW, Allis CD. Ubiquitination of histone H2B regulates H3 methylation and gene silencing in yeast. Nature. 2002;418:104–8.PubMed

116.

Higashi M, Inoue S, Ito T. Core histone H2A ubiquitylation and transcriptional regulation. Exp Cell Res. 2010;316:2707–12.PubMed

117.

Chandrasekharan MB, Huang F, Sun Z-W. Histone H2B ubiquitination and beyond. Epigenetics. 2010;5:460–8.PubMedCentralPubMed

118.

Laribee RN, Fuchs SM, Strahl BD. H2B ubiquitination in transcriptional control: a FACT-finding mission. Genes Dev. 2007;21:737–43.PubMed

119.

Ezhkova E, Tansey WP. Proteasomal ATPases link ubiquitylation of histone H2B to methylation of histone H3. Mol Cell. 2004;13:435–42.PubMed

120.

Logan IR, Gaughan L, McCracken SRC, et al. Human PIRH2 enhances androgen receptor signalling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer. Mol Cell Biol. 2006;26:6502–10.PubMedCentralPubMed

121.

Boeger H, Bushnell DA, Davis R, et al. Structural basis of eukaryotic gene transcription. FEBS Lett. 2005;579:899–903.PubMed

122.

Boeger H, Griesenbeck J, Strattan JS, Kornberg RD. Removal of promoter nucleosomes by disassembly rather than sliding in vivo. Mol Cell. 2004;14:667–73.PubMed

123.

Gaughan L, Logan IR, Neal DE, Robson CN. Regulation of androgen receptor and histone deacetylase 1 by mdm2-mediated ubiquitylation. Nucleic Acids Res. 2005;33:13–26.PubMedCentralPubMed

124.

Ramamoorthy S, Nawaz Z. E6-associated protein (E6-AP) is a dual function coactivator of steroid hormone receptors. Nucl Recept Signal. 2008;6:e006.PubMedCentralPubMed

125.

Vijayvargia R, May MS, Fondell JD. A coregulatory role for the mediator complex in prostate cancer cell proliferation and gene expression. Cancer Res. 2007;67:4034–41.PubMed

126.

Conaway RC, Brower CS, Conaway JW. Emerging roles of ubiquitin in transcriptional regulation. Science. 2002;296:1254–8.PubMed

127.

Burgdorf S, Leister P, Scheidtmann KH. TSG101 interacts with apoptosis-antagonizing transcription factor and enhances androgen receptor-mediated transcription by promoting its monoubiquitination. J Biol Chem. 2004;279:17524–34.PubMed

128.

Kajiro M, Hirota R, Nakajima Y, et al. The ubiquitin ligase CHIP acts as an upstream regulator of oncogenic pathways. Nat Cell Biol. 2009;11:312–9.PubMed

129.

Patterson C, Ronnebaum S. Breast cancer quality control. Nat Cell Biol. 2009;11:239–41.PubMed

130.

Lipkowitz S, Weissman AM. RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nature Rev Cancer. 2011;11:629–43.

131.

Soucy TA, Dick LR, Smith PG, et al. The NEDD8 conjugation pathway and its relevance in cancer biology and therapy. Genes Cancer. 2010;1:708–16.PubMedCentralPubMed

132.

Kim S-E, Yoon J-Y, Jeong W-J, et al. H-Ras is degraded by Wnt/β-catenin signaling via β-TrCP-mediated polyubiquitination. J Cell Sci. 2009;122:842–8.PubMed

133.

Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer. Nature Rev Cancer. 2008;8:438–49.

134.

von der Lehr N, Johansson S, Wu S, et al. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell. 2003;11:1189–200.PubMed

135.

Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nature Rev Cancer. 2008;8:83–93.

136.

O’Neal J, Grim J, Strack P, et al. (2005) FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors. J Exp Med. 2007;204:1813–24.

137.

Minella AC, Welcker M, Clurman BE. Ras activity regulates cyclin E degradation by the Fbw7 pathway. Proc Natl Acad Sci USA. 2005;102:9649–54.PubMedCentralPubMed

138.

Sarikas A, Xu X, Field LJ, Pan Z-Q. The cullin7 E3 ligase: a novel player in growth control. Cell Cycle. 2008;7:3154–61.PubMed

139.

Jung P, Verdoodt B, Bailey A, et al. Induction of cullin 7 by DNA damage attenuates p53 function. Proc Natl Acad Sci USA. 2007;104:11388–93.PubMedCentralPubMed

140.

Nikolaev AY, Li M, Puskas N, et al. Parc: a cytoplasmic anchor for p53. Cell. 2003;112:29–40.PubMed

141.

Kaelin Jr WG. The von Hippel–Lindau tumour suppressor protein: O₂ sensing and cancer. Nature Rev Cancer. 2008;8:865–73.

142.

Harten SK, Shukla D, Barod R, et al. Regulation of renal epithelial tight junctions by the von Hippel–Lindau tumor suppressor gene involves occludin and claudin 1 and is independent of E-cadherin. Mol Biol Cell. 2009;20:1089–101.PubMedCentralPubMed

143.

Parant J, Chavez-Reyes A, Little NA, et al. Rescue of embryonic lethality in MDM4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nature. 2001;29:92–5.

144.

Perry ME. The regulation of the p53-mediated stress response by MDM2 and MDM4. Cold Spring Harb Perspect Biol. 2010;2:a000968.PubMedCentralPubMed

145.

Marine J-C, Lozano G. Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Diff. 2010;17:93–102.

146.

Barboza JA, Iwakuma T, Terzian T, et al. MDM2 and MDM4 loss regulates distinct p53 activities. Mol Cancer Res. 2008;6:947–54.PubMedCentralPubMed

147.

Manfredi JJ. The Mdm2–p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev. 2010;24:1580–9.PubMedCentralPubMed

148.

Araki S, Eitel JA, Batuello CN, et al. TGF-β1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer. J Clin Invest. 2010;120:290–302.PubMed

149.

Ries S, Biederer C, Woods D, et al. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19^ARF. Cell. 2000;103:321–30.PubMed

150.

Phelps M, Darley M, Primrose JN, Blaydes JP. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor α-positive breast cancer cells. Cancer Res. 2003;63:2616–23.PubMed

151.

Phelps M, Phillips A, Darley M, Blaydes JP. MEK–ERK signalling controls Hdm2 oncoprotein expression by regulating hdm2 mRNA export to the cytoplasm. J Biol Chem. 2005;280:16651–8.PubMed

152.

Cicalese A, Bonizzi G, Pasi CE, et al. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell. 2009;138:1083–95.PubMed

153.

Allende-Vega N, Saville MK. Targeting the ubiquitin–proteasome system to activate wild-type p53 for cancer therapy. Sem Cancer Biol. 2010;20:29–39.

154.

Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med. 2007;13:23–31.PubMed

155.

Zhuang C, Miao Z, Zhu L, et al. Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53–MDM2 protein–protein interaction. Eur J Med Chem. 2011;46:5654–61.PubMed

Titel: Ubiquitination and the Ubiquitin–Proteasome System as regulators of transcription and transcription factorsin epithelial mesenchymal transition of cancer
verfasst von: Ioannis A. Voutsadakis
Publikationsdatum: 01.08.2012
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 4/2012
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-012-0355-x

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Ubiquitination and the Ubiquitin–Proteasome System as regulators of transcription and transcription factorsin epithelial mesenchymal transition of cancer

Abstract

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

Association between FTO gene polymorphism and cancer risk: evidence from 16,277 cases and 31,153 controls

Meta-analyses of the associations between four common TGF-β1 genetic polymorphisms and risk of colorectal tumor

Serum C-reactive protein as an important prognostic variable in patients with diffuse large B cell lymphoma

Involvement of heme oxygenase-1 in Korean colon cancer

Tumor microsomal metabolism of the food toxicant, benzo(a)pyrene, in Apc Min mouse model of colon cancer

Prognostic significance of transforming growth factor beta (TGF-β) signaling axis molecules and E-cadherin in colorectal cancer

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie